张怡，博士，副教授，博士生导师。

主要研究方向为卫生法学、全球卫生治理、药品监管科学。

《中华人民共和国疫苗管理法》起草专家组成员；《中华人民共和国传染病防治法》修改完善评估工作组成员；《中华人民共和国药品管理法实施条例》修订专家组成员；世界卫生组织《大流行协定》和《国际卫生条例（2005）》制修订谈判中方代表。

教育经历

2013.11 - 2018.05 荷兰格罗宁根大学 法学院 法学博士

工作经历

2026.01 - 至今       清华大学，卫健学院，副教授

2022.08 - 2026.01 清华大学，卫健学院，助理教授

2018.09 - 2022.07 清华大学，法学院，助理研究员/博士后

研究领域

1. 医药卫生法

2. 全球卫生治理

3. 生物医药新技术监管

（本课题组长期招收博士后和科研助理，联系方式：yi_zhang@mail.tsinghua.edu.cn)

学术兼职

荣誉奖励

清华大学法学院优秀博士后（2022）

荷兰格罗宁根大学法学院优等毕业（2018）

中国博士后国际交流计划引进项目（2019）

清华大学博士后支持计划（2018）

学术成果（部分）：

1. Shen T, Wang X, Zhang Y* and Zhang Y*, How generative AI reconfigure clinician-AI and clinician-patient relationships. Clinical and Translational Medicine. 2026;16 (2):e70606.

2. Du X, Zhao Z, Sun X, Zhang Y, Zhang Y* and Luo X*, Challenges for Chinese Cancer Innovative Drugs in Going Global: Insights from Multiregional Clinical Trials. The Lancet Oncology. 2025; 26: e558–69

3. Zhang Y, Li J, van den Dool A*, China’s Revised Infectious Diseases Law: A Step Towards Stronger Global Pandemic Preparedness. The Lancet Regional Health–Western Pacific. 2025, 63: 101708.

4. Shen T, Li Y, Cao Y, Du X, Wang X, Zhang Y* and Zhang Y*, Rapid Deployment of Large language Model DeepSeek in Chinese hospitals Demands A Regulatory Response. Nature Medicine. 2025; 31: 3233–3238.

5. Mao Y#, Zhang Y#, Cao Y*, Can DeepSeek Transform Healthcare in Low- and Middle-income Countries? Equity, Governance, and Deployment Strategies. The Innovation. 2025, 6 (12):101009.

6. Min K#, Zhang Y#, Liu J#, Yang J, Cao F*, Peng Z*, Liu D*, China’s Biosafety/biosecurity governance: evolution, challenges, and architecture design. Frontiers of Medicine. 2025 (online). doi:10.1007/s11684-025-1158-y.

7. Du X, Luo X, Liu L, Cao Y, Zhang Y* and Zhang Y*, Mapping the Cell Therapy Landscape: Insights into Clinical Trials and Regulatory Advances in China. Journal of Hematology & Oncology. 2024; 17:96.

8. Du X, Luo X, Guo Q, Jiang X, Su Z, Zhou W, Wang Z, Li J, Yang Y* and Zhang Y*, Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China. Frontiers in Public Health. 2024; 12:1476213.

9. Zhang Y*, Guo Y, To Tier or Not to Tier: The Institutionalization of the World Health Organization’s power to Determine Pandemic Emergency in The Amended International Health Regulations (2005). Global Health Research and Policy. 2025,10 (40).

10. Zhang Y, Wang C, ‘Internet Plus Health Care’ as an impetus for China’s health system reform’ in Cohen G., Kramer D., et al (eds), Digital Health Care outside of Traditional Clinical Settings: Ethical, Legal, and Regulatory Challenges and Opportunities (Cambridge University Press 2024).

11. Wang C, Zhang Y*, ‘Common but differentiated responsibilities and respective capabilities as a guiding principle in international health law in times of pandemics’ in M Heijer and H Wilt (eds), Netherlands Yearbook of International Law 2020 (Springer 2022).

12. Zhang Y, ‘Exploring the role of ASEAN in fostering human rights approaches to tobacco control in Asia’ in Gispen ME and Toebes BCA (eds), Human Rights and Tobacco Control (Edward Elgar Publishing 2020).

13. Zhang Y, Advancing the Right to Health Care - Towards Accountability (Intersentia 2019).

14. 张雅娟, 杜鑫, 张怡*, 美国药品监管科学战略规划及其对中国药品监管的借鉴. 中国新药与临床杂志. 2025,44 (03):161-167.

15. 刘杰, 张怡, 何清清,以制促治：我国地方药品监管能力提升路径. 中国行政管理. 2022, (08):157-160.

16. 参与撰写多篇咨询报告，其中四篇被中国法学会《要报》采纳，获得中央领导同志重要批示；四篇获得省部级领导批示。